Ned Sharpless is not playing with the FDA’s gold standard — any more than Scott Gottlieb did
Ned Sharpless got a chance to outline just what kind of acting FDA chief he’ll be in the wake of Scott Gottlieb’s departure from the agency. And aside from a more conservative selection of socks, he’s clearly planning to adopt the exact same fashions laid down by his predecessor.
In an all-hands-on-deck address to staffers, Sharpless promised to fit the Gottlieb mold perfectly, vowing to maintain the agency’s gold standard on drug approvals while doing what he can to keep the copycats coming to help tamp down on drug costs.
So let me reassure you, I am not planning any radical changes from what the FDA has been trying to accomplish.